united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
Company profile
Ticker
UTHR
Exchange
Website
CEO
Martine Rothblatt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
IVIVA Medical, Inc. • Lung Bioengineering Inc. • Lung Biotechnology PBC, a Delaware public benefit corporation • Miromatrix Medical Inc. • Revivicor, Inc. • United Therapeutics Europe, Ltd., a company incorporated • United Therapeutics Ireland Limited, a company incorporated • Unither Biotech Inc. • Unither Bioelectronics, Inc. • Unither Pharma, LLC ...
IRS number
521984749
UTHR stock data
Latest filings (excl ownership)
SD
Conflict minerals disclosure
31 May 24
8-K
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
1 May 24
10-Q
2024 Q1
Quarterly report
1 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Entry into a Material Definitive Agreement
29 Mar 24
8-K
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
25 Mar 24
8-K
Other Events
27 Feb 24
8-K
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
Transcripts
UTHR
Earnings call transcript
2024 Q1
1 May 24
UTHR
Earnings call transcript
2023 Q4
21 Feb 24
UTHR
Earnings call transcript
2023 Q3
1 Nov 23
UTHR
Earnings call transcript
2023 Q2
2 Aug 23
UTHR
Earnings call transcript
2023 Q1
3 May 23
UTHR
Earnings call transcript
2022 Q4
22 Feb 23
UTHR
Earnings call transcript
2022 Q3
2 Nov 22
UTHR
Earnings call transcript
2022 Q2
3 Aug 22
UTHR
Earnings call transcript
2022 Q1
4 May 22
UTHR
Earnings call transcript
2021 Q4
27 Feb 22
Latest ownership filings
4
MARTINE A ROTHBLATT
30 May 24
4
MARTINE A ROTHBLATT
28 May 24
4
MARTINE A ROTHBLATT
23 May 24
4
MARTINE A ROTHBLATT
22 May 24
4
MARTINE A ROTHBLATT
20 May 24
4
CHRISTOPHER CAUSEY
16 May 24
4
JAMES EDGEMOND
16 May 24
4
MARTINE A ROTHBLATT
16 May 24
4
CHRISTOPHER PATUSKY
15 May 24
144
Notice of proposed sale of securities
15 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 497 |
Opened positions | 160 |
Closed positions | 64 |
Increased positions | 146 |
Reduced positions | 128 |
13F shares | Current |
---|---|
Total value | 9.10 tn |
Total shares | 46.14 mm |
Total puts | 529.40 k |
Total calls | 500.90 k |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 5.57 mm | $1.28 tn |
Vanguard | 4.68 mm | $1.08 tn |
Wellington Management | 3.41 mm | $783.86 bn |
Avoro Capital Advisors | 2.86 mm | $656.74 bn |
Integrated Core Strategies | 2.24 mm | $175.63 mm |
Renaissance Technologies | 2.15 mm | $494.29 mm |
STT State Street | 1.94 mm | $444.54 bn |
FMR | 1.02 mm | $233.77 bn |
Aqr Capital Management | 846.96 k | $194.56 bn |
Geode Capital Management | 828.27 k | $190.05 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 May 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 268.3523 | 1,082 | 290.36 k | 130 |
29 May 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 267.5931 | 1,212 | 324.32 k | 1,212 |
29 May 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 265.9704 | 805 | 214.11 k | 2,424 |
29 May 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 265.2222 | 501 | 132.88 k | 3,229 |
29 May 24 | Rothblatt Martine A | Common Stock | Option exercise | Acquire M | No | Yes | 129.49 | 3,600 | 466.16 k | 3,730 |
29 May 24 | Rothblatt Martine A | Stock Options Common Stock | Option exercise | Dispose M | No | Yes | 129.49 | 3,600 | 466.16 k | 216,269 |
28 May 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 271.262 | 86 | 23.33 k | 130 |
28 May 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 269.5359 | 1,442 | 388.67 k | 216 |
28 May 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 268.7847 | 1,776 | 477.36 k | 1,658 |
28 May 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 267.7687 | 296 | 79.26 k | 3,434 |
News
Expert Ratings For United Therapeutics
21 May 24
JP Morgan Maintains Overweight on United Therapeutics, Raises Price Target to $300
21 May 24
Perrigo Q1 Earnings Surpass, Sales Miss Estimates
9 May 24
Goldman Sachs Maintains Neutral on United Therapeutics, Raises Price Target to $240
3 May 24
The Latest Analyst Ratings For United Therapeutics
2 May 24
Press releases
MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention
31 May 24
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
1 May 24
United Therapeutics Announces World's First Successful Xenothymokidney Transplant
24 Apr 24
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
16 Apr 24
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
25 Mar 24